M2N Co., Ltd.
KKRX:0333101,324.00
KRW
-23.00
(-1.71%)
ISIN
KR7033310004
Return %
Stock
S&P 500
1Y
-28.97
14.39
3Y
-56.38
81.42
5Y
-89.62
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Seung-Geon Lee
- Full Time Employees
- 208
- Sector
- Producer manufacturing
- Industry
- Metal fabrication
- Address
- Seoul South Korea
- IPO Date
- Nov 10, 1997
- Website
- dkdni.co.kr
- Similar Companies
- Business
- M2N Co., Ltd. is a South Korea-based company primarily engaged in the manufacturing and distribution of steel packaging components, specialized coated steel sheets, and industrial materials, with diversified operations spanning biopharmaceuticals, healthcare technologies, and automotive thermal management solutions. Founded in 1978 and headquartered in Seoul, South Korea, the company operates across manufacturing, advanced materials, and life sciences divisions to serve both domestic and international markets. The company's core product and service portfolio comprises industrial steel drum parts and closures; bungs, flanges, and tamper-evident cap seals for chemical, petrochemical, and food-grade liquid storage containers; pre-coated metal (PCM) and laminated steel sheets designed for consumer appliances such as refrigerators, air conditioners, and washing machines; surface-treated and color-coated steel panels for interior and exterior architectural applications; and cold-rolled galvanized steel coils. Through its biopharmaceutical subsidiaries and strategic investments, including its majority-controlled affiliate SillaJen, Inc. and US-based Greenfire Bio LLC, the company provides novel immuno-oncology research and clinical-stage therapeutics; including oncolytic virus platforms such as Pexa-Vec (pexastimogene devacirepvec), BAL0891 dual-kinase inhibitor clinical development programs, and SJ-600 series genetically modified virus pipelines targeting solid tumors. M2N supplies global industrial packaging converters, appliance manufacturers, construction contractors, and clinical trial partners throughout South Korea, North America, Europe, and the Asia-Pacific region. In recent strategic developments, the company has transformed its corporate structure from a traditional industrial steel manufacturer into a multifaceted holding and development entity, following its corporate name change from DK Dongshin Co., Ltd. to M2N Co., Ltd. The company executed the strategic acquisition and financial rehabilitation of SillaJen, driving the resumption and expansion of global Phase 1/2 oncology clinical trials and forging research alliances with international clinical development organizations. Concurrently, M2N has expanded its operations into eco-friendly mobility solutions, developing thermal management system components, specialized heat-dissipating materials, and high-efficiency fluid control parts for electric vehicle (EV) battery and powertrain systems, while upgrading automated manufacturing lines across its domestic production facilities to optimize operational efficiency.